| Abstract: |
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer. |
| Inventor: |
Farr, Stephen J. (Orinda, CA, US); Boyd, Brooks (Berkeley, CA, US) |
| Applicant: |
ZOGENIX INTERNATIONAL LIMITED (Berkshire, GB) |
| Face Assignee: |
ZOGENIX INTERNATIONAL LIMITED (Berkshire, GB) |
| Filed: |
2018-11-16 |
| Issued: |
2020-03-31 |
| Claims: |
10 |
|
US10603290
|
1. A method of reducing or ameliorating seizures in a patient, comprising:
(3)
(2)
|
|
5. A method of reducing or ameliorating seizures in a patient diagnosed with a form of refractory epilepsy, comprising:
(0)
(2)
|
|
6. A method of reducing or ameliorating seizures in a patient diagnosed with a form of refractory epilepsy, comprising:
(2)
(1)
|
|
9. A method of reducing or ameliorating seizures patient diagnosed with Dravet syndrome, comprising:
(0)
(2)
|
|
10. A method of reducing or ameliorating seizures in a patient diagnosed with Dravet syndrome, comprising:
(0)
(1)
|
|
